Publicacións nas que colabora con José Ángel Martínez Climent (26)

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  3. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2020

  1. CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation

    Blood Advances, Vol. 4, Núm. 5, pp. 893-906

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

2018

  1. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573

  2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

  3. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

2015

  1. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations

    BMC Genomics, Vol. 16, Núm. 1

2013

  1. Downregulation of FOXP1 is required during germinal center B-cell function

    Blood, Vol. 121, Núm. 21, pp. 4311-4320

  2. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas

    British Journal of Haematology, Vol. 162, Núm. 5, pp. 621-630

2012

  1. Epigenetic regulation of miRNA genes in acute leukemia

    Leukemia, Vol. 26, Núm. 3, pp. 395-403

  2. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma

    British Journal of Haematology, Vol. 158, Núm. 6, pp. 712-726

  3. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2011

  1. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, Núm. 30, pp. 12461-12466